Lilly,Seamless Ink Up-to-$1.12B Hearing Loss Collaboration

Abstract

Get full access to this article

View all access options for this article.

References

Philippidis

. Seamless Ink Up-to-$1.12B Hearing Loss Collaboration. Genetic Engineering & Biotechnology News, 2026. Available from: https://www.genengnews.com/topics/genome-editing/lilly-seamless-ink-up-to-1-12b-hearing-loss-collaboration/ [Last accessed: February 1, 2026].

Seamless Therapeutics. Seamless Therapeutics Announces Global Research Collaboration with Lilly to Develop Programmable Recombinase-based Therapeutics for Hearing Loss. 2026. Available from: https://www.globenewswire.com/news-release/2026/01/28/3227440/0/en/Seamless-Therapeutics-Announces-Global-Research-Collaboration-with-Lilly-to-Develop-Programmable-Recombinase-based-Therapeutics-for-Hearing-Loss.html [Last accessed: February 1, 2026].

REGENXBIO. REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs. 2026. Available from: https://ir.regenxbio.com/news-releases/news-release-details/regenxbio-announces-regulatory-update-ultra-rare-mps-programs [Last accessed: January 30, 2026].

Eli Lilly & Co. Q4 2025 Lilly Presentation. 2026. Available from: https://investor.lilly.com/static-files/45a92498-43d0-4e2d-a4e6-a9131841cfd6 [Last accessed: February 5, 2026].

Masson

. Biotech Lilly drops 3 pipeline drugs, including gene therapy from $1B Prevail buyout. 2026. Available from: https://www.fiercebiotech.com/biotech/lilly-drops-3-pipeline-drugs-including-gene-therapy-1b-prevail-buyout [Last accessed: February 5, 2026].

Ultragenyx Pharmaceutical. Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA). 2026. Available from: https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-announces-positive-longer-term-data-demonstrating [Last accessed: February 3, 2026].

Ultragenyx Pharmaceutical. Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA. 2026. Available from: https://ir.ultragenyx.com/news-releases/news-release-details/ultragenyx-resubmits-biologics-license-application-ux111-aav [Last accessed: February 3, 2026].

Taysha Gene Therapies. Taysha Gene Therapies Announces Progress Across TSHA-102 Pivotal Gene Therapy Program in Rett Syndrome. Available from: 2026. https://ir.tayshagtx.com/news-releases/news-release-details/taysha-gene-therapies-announces-progress-across-tsha-102-pivotal [Last accessed: February 1, 2026].

Sensorion. Sensorion Announces €60 Million Financing With a €20M Strategic Investment from Sanofi and Support from Global Healthcare Specialists To Advance Genetic Medicine Pipeline. 2026. Available from: https://s27.q4cdn.com/232015521/files/doc_news/Sensorion-Announces-60-Million-Financing-With-a-20M-Strategic-Investment-from-Sanofi-and-Support-from-Global-Healthcare-Specialists-T-X4SDP.pdf [Last accessed: February 1, 2026].

10.

Sarepta Therapeutics. Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients. 2026. Available from: https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-announces-positive-topline-three-year-embark-results [Last accessed: February 3, 2026].